Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

$24.99

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

Johnson & Johnson, profitability ratios (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).


The analysis of the quarterly financial data reveals several notable trends across profitability and efficiency metrics over the observed periods.

Gross Profit Margin
The gross profit margin shows a consistent upward trend from the first available data point in March 2020, starting at 65.58%, and gradually increasing to a peak of 69.2% in December 2023. After this peak, there is a slight decline reaching 67.92% by June 2025. This pattern indicates an overall improvement in the company's cost management relative to revenue, with a slight weakening towards the latest quarters.
Operating Profit Margin
Operating profit margin exhibits a generally stable trajectory with minor fluctuations. It starts at 23.6% in March 2020, increases gradually to around 25.61% in October 2023, and then experiences a modest decline to 23.59% by June 2025. The data suggests that operational efficiency has been maintained at a solid level, though it shows some pressure in the most recent quarters.
Net Profit Margin
The net profit margin shows greater volatility compared to gross and operating margins. It rises progressively reaching a significant peak of 44.92% in October 2023, representing a period of pronounced profitability. However, this is followed by a sharp decrease to 15.84% by July 2024, with a partial recovery to 25% by June 2025. The fluctuations imply episodic factors affecting bottom-line profitability, possibly related to non-operating items or extraordinary events.
Return on Equity (ROE)
ROE follows a similar pattern to net profit margin with steady growth up to 54.95% in October 2023, indicating strong shareholder returns. Subsequently, it drops noticeably to 19.68% in July 2024 and then rises again to nearly 29% by June 2025. This reflects a cyclical nature in equity profitability consistent with the net profit margin trends.
Return on Assets (ROA)
ROA shows a gradual increase early in the dataset, peaking at 22.37% in October 2023, before experiencing a decline to 7.81% in July 2024 with a moderate recovery to 11.72% by June 2025. The changes suggest varying efficiency in asset utilization over time, likely influenced by the same factors affecting net income and equity returns.

Overall, the data portrays a period of progressive improvement in margins and returns culminating around late 2023, followed by a phase of notable contraction and partial recovery. This pattern may reflect external market pressures, company-specific events, or accounting impacts influencing profitability and returns on capital and assets. The relative stability of gross and operating margins contrasts with the volatility in net margins and return ratios, indicating that fluctuations primarily arise from below-the-operating-line factors or changes in financial structure.


Return on Sales


Return on Investment


Gross Profit Margin

Johnson & Johnson, gross profit margin calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Gross profit
Sales to customers
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Gross profit margin = 100 × (Gross profitQ2 2025 + Gross profitQ1 2025 + Gross profitQ4 2024 + Gross profitQ3 2024) ÷ (Sales to customersQ2 2025 + Sales to customersQ1 2025 + Sales to customersQ4 2024 + Sales to customersQ3 2024)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The financial data for the company over the analyzed quarters reveal several notable trends in gross profit, sales to customers, and gross profit margin.

Gross Profit
Gross profit exhibits a general upward trend from the early quarters through to the later periods, reflecting increasing profitability before cost of goods sold. There is a clear growth from approximately 13,629 million US dollars in March 2020 to a peak of about 16,849 million US dollars in December 2021. However, after this peak, gross profit fluctuates with several declines and rebounds, notably decreasing in the first quarter of 2023 to 14,207 million US dollars, followed by partial recovery and then again falling towards 14,536 million US dollars by the end of March 2025. This suggests some volatility in costs or prices affecting profitability despite overall growth over the entire period.
Sales to Customers
Sales to customers show a strong increase from 20,691 million US dollars in March 2020 to a higher level of around 24,804 million US dollars by the end of 2021, indicating steady revenue growth. Following this peak, sales remain relatively stable with minor fluctuations, staying around the 21,000 to 23,700 million US dollars range in subsequent quarters. The latest data points towards a slight decline in sales towards the first half of 2025 compared to prior peaks, signaling potential challenges in revenue generation or market saturation.
Gross Profit Margin
The gross profit margin demonstrates a positive trend, improving steadily from approximately 65.58% in late 2020 to a range between roughly 67% and 69% in the following years. This suggests enhanced efficiency either through cost management or improved pricing strategy. The margin peaks near 69.2% in December 2023 and then remains relatively stable around 68% towards the later quarters. This stability indicates the company maintains its profitability at the gross level despite fluctuations in absolute profit and sales figures.

Overall, the data indicates a company managing to improve gross profitability and margin over the medium term while experiencing some variability in absolute profit and sales figures. The strengthening gross profit margin highlights effective cost control or pricing power, even as sales growth shows signs of slowing or plateauing in recent quarters.


Operating Profit Margin

Johnson & Johnson, operating profit margin calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Operating earnings
Sales to customers
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Operating profit margin = 100 × (Operating earningsQ2 2025 + Operating earningsQ1 2025 + Operating earningsQ4 2024 + Operating earningsQ3 2024) ÷ (Sales to customersQ2 2025 + Sales to customersQ1 2025 + Sales to customersQ4 2024 + Sales to customersQ3 2024)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The financial data reveals several notable trends over the observed periods. Sales to customers have generally shown a fluctuating but overall stable pattern around the range of approximately 20,000 to 24,800 million US dollars, with occasional peaks and troughs but no dramatic long-term increase or decrease. This suggests relatively consistent market demand or pricing over the quarters.

Operating earnings display greater volatility compared to sales. Early periods show some quarters with higher earnings (such as Mar 29, 2020, and Apr 4, 2021) followed by declines in subsequent quarters. Notably, a downward trend in operating earnings appears toward the later quarters, particularly in Dec 31, 2023, and Mar 31, 2024, with values dipping below the earlier average levels. However, some rebounds are visible in the most recent quarters, indicating potential recovery or improved operational performance.

The operating profit margin, which is only available from the quarter ending Dec 31, 2020, through the most recent periods, remains fairly consistent, ranging approximately from 23.4% to 25.6%. This stability in margin percentages suggests controlled costs relative to sales throughout the periods analyzed. Margins peaked around Oct 1, 2023, indicating particularly efficient operations or favorable pricing conditions in that quarter, but slightly decreased thereafter, reflecting some variability in profitability despite steady sales levels.

Overall, the data points to a stable sales base with somewhat fluctuating operating earnings and steady profit margins, indicating consistent operational efficiency but volatility in absolute earnings possibly due to external economic factors, one-time expenses, or changes in cost structure. The slight margin decline in the latest periods may warrant closer examination to identify underlying causes.

Sales to Customers
Generally consistent with minor fluctuations around 20,000 to 24,800 million US dollars, no significant upward or downward trend.
Operating Earnings
Exhibit volatility with peaks and troughs; notable declines in some recent quarters, yet signs of recovery appear toward the end of the dataset.
Operating Profit Margin
Relatively stable between 23.4% and 25.6% since data availability began; margins peaked near Oct 2023 before a slight decline.

Net Profit Margin

Johnson & Johnson, net profit margin calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Net earnings (loss)
Sales to customers
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
Net profit margin = 100 × (Net earnings (loss)Q2 2025 + Net earnings (loss)Q1 2025 + Net earnings (loss)Q4 2024 + Net earnings (loss)Q3 2024) ÷ (Sales to customersQ2 2025 + Sales to customersQ1 2025 + Sales to customersQ4 2024 + Sales to customersQ3 2024)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The financial data exhibits significant fluctuations in net earnings over the observed quarters. Initially, net earnings declined sharply from 5,796 million US$ in the first quarter of 2020 to 1,738 million US$ by the fourth quarter of 2020. Following this period, net earnings rebounded and showed variability, with notable peaks such as 26,028 million US$ in the fourth quarter of 2023, indicating a substantial one-time gain or exceptional performance during that period. However, this peak is followed by more moderate figures in subsequent quarters, oscillating between approximately 3,000 and 11,000 million US$.

Sales to customers display a relatively stable trend with minor fluctuations. Sales peaked around the fourth quarter of 2021 at approximately 24,804 million US$, followed by slight decreases and increases with values generally ranging between 20,800 and 23,700 million US$. Despite fluctuations in net earnings, sales have maintained a consistent level, suggesting stable demand or consistent operational output.

The net profit margin shows an initially missing data portion but is calculable from the fourth quarter of 2020 onward. The margin generally remains in a range between approximately 14% and 22% initially, indicating healthy profitability levels in relation to sales. A remarkable spike occurs in the fourth quarter of 2023 and first two quarters of 2024, with margins exceeding 39%, peaking near 45%. This anomaly corresponds to the large net earnings figure noted in the same timeframe. Subsequently, margins revert to more typical levels around 16% to 25%, indicating the spike was an outlier likely driven by extraordinary items influencing net earnings disproportionately to sales.

Overall, the data reveals strong operational sales performance with consistent revenue generation, while net earnings and profitability margins exhibit high volatility, particularly linked to extraordinary circumstances or one-off events in late 2023. This variability suggests that while the core business remains stable, profitability is subject to episodic fluctuations that materially impact reported earnings and margins.

Net Earnings Trend
Declining through 2020, recovery with volatility, major spike in late 2023, followed by stabilization at mid-range values.
Sales Performance
Relatively stable over time, slight fluctuations within a narrow range, no significant upward or downward long-term trend.
Net Profit Margin
Consistently healthy margins between 14% and 22%, extraordinary spike above 39% in late 2023 to mid-2024, returning to moderate levels thereafter.
Insights
Core business generates steady sales, but profitability and net earnings are influenced by exceptional items. Careful consideration of these outliers is necessary for performance evaluation.

Return on Equity (ROE)

Johnson & Johnson, ROE calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Net earnings (loss)
Total Johnson & Johnson shareholders’ equity
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
ROE = 100 × (Net earnings (loss)Q2 2025 + Net earnings (loss)Q1 2025 + Net earnings (loss)Q4 2024 + Net earnings (loss)Q3 2024) ÷ Total Johnson & Johnson shareholders’ equity
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several notable trends in earnings, equity, and return on equity (ROE) over the observed periods.

Net Earnings (Loss)
The net earnings demonstrate considerable volatility throughout the reported quarters. Initially, the earnings decline sharply from a high of 5,796 million US dollars in Mar 29, 2020 to 1,738 million US dollars by Dec 31, 2020. Following this trough, earnings generally recover, reaching a peak of 26,028 million US dollars in Oct 1, 2023, which represents a significant surge compared to prior periods. However, this spike appears to be an anomaly, as earnings revert to lower levels (4,049 million in Mar 31, 2024). Subsequent quarters display fluctuations with no consistent upward or downward trend, indicating variability in profitability.
Total Shareholders’ Equity
The total shareholders' equity exhibits a steady growth trend over the timeline. Starting at 61,294 million US dollars in Mar 29, 2020, equity increases gradually with minor fluctuations, reaching 78,473 million US dollars by Jun 29, 2025. Despite small decreases in certain quarters (e.g., Dec 31, 2022 and Mar 2, 2023), the overall trend is positive, signifying accumulated retained earnings and possible capital injections or asset growth.
Return on Equity (ROE)
The ROE data, available from Dec 31, 2020 onward, shows strong performance with values generally exceeding 20%. The ROE fluctuates around the mid-20% range up to Dec 31, 2022 but then experiences a remarkable increase, peaking at 54.95% in Sep 29, 2024. This indicates increased profitability and efficient equity utilization during that period. After this peak, ROE declines sharply to 19.68% by Jun 29, 2025, suggesting that the superior returns were not sustained. The elevated ROE values in late 2023 and 2024 correspond with the substantial spike in net earnings during the same timeframe.

In summary, the data indicates a stable growth in shareholders' equity, substantial variability in net earnings with an extraordinary spike in late 2023, and a strong but fluctuating ROE performance. The extraordinary earnings and ROE values in 2023 and 2024 deserve attention as potential outliers or effects of extraordinary events impacting financial results within this timeline.


Return on Assets (ROA)

Johnson & Johnson, ROA calculation (quarterly data)

Microsoft Excel
Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Net earnings (loss)
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q2 2025 Calculation
ROA = 100 × (Net earnings (loss)Q2 2025 + Net earnings (loss)Q1 2025 + Net earnings (loss)Q4 2024 + Net earnings (loss)Q3 2024) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


Net Earnings (Loss)
The net earnings demonstrated notable volatility over the reported periods. Beginning at $5,796 million in March 2020, earnings declined sharply to a low of $1,738 million by December 2020. A recovery phase followed with fluctuations, reaching a peak of $26,028 million in October 2023, before declining again in subsequent quarters to $5,537 million by June 2025. The data reveals intermittent substantial increases and decreases, suggesting variability in profitability possibly influenced by external factors or internal operational changes.
Total Assets
Total assets showed a general upward trend with some variability. Starting at $155,017 million in March 2020, assets increased steadily, peaking at $195,969 million in April 2023. This was followed by a decline to $166,061 million in October 2023, after which the total assets rose again to approximately $193,389 million by June 2025. The fluctuations may indicate strategic asset acquisitions or disposals, or shifts in asset valuation over time.
Return on Assets (ROA)
The ROA percentages, available beginning in December 2020, illustrate an overall positive performance trend. Initially showing values around 8.41% to 10.94%, ROA improved significantly, peaking at 22.37% in September 2024. This represents enhanced efficiency in asset utilization to generate earnings. The latter part of the series shows moderate reductions but remains above 7%, indicating sustained effective use of assets despite the variability in earnings and asset totals.
Overall Trends and Insights
The financial data display significant variability in earnings accompanied by fluctuations in total assets. Despite earnings volatility, the ROA trend illustrates improving asset efficiency over time. The spike in net earnings around late 2023 corresponds with a temporary reduction in total assets, which may indicate asset sales or restructuring contributing to the profit surge. Following this peak, earnings and assets stabilize at elevated levels compared to early 2020. These patterns suggest periods of operational adjustment, strategic asset management, and varying profitability performance.